Evidence map›Paper›PMID 40676441›Full record

ArticleDiscover oncology2025

Unveiling the predictive role of systemic inflammation marker in mortality outcomes: a nationwide analysis of cancer survivorship in the United States.

Angshu Cai, Bowen Zha, Chen Zhang, Shuying Guo, Guiqi Wang, Shun He

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Angshu Cai *Department of Endoscopy, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China.
Bowen Zha *Department of Endoscopy, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China.
Chen ZhangDepartment of Endoscopy, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China.
Shuying GuoDepartment of Endoscopy, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China.
Guiqi WangDepartment of Endoscopy, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China. wangguiq@126.com.
Shun HeDepartment of Endoscopy, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China. heshuns@126.com.

Funding

Beijing Hope Run Special Fund of Cancer Foundation of China grant no. LC2021A03CAMS Innovation Fund for Medical Sciences (CIFMS) grant no. 2021-I2M-1-015, 2021-I2M-1-061, 2021-I2M-1-013, 2022-I2M-C&T-B-054Capital's Funds for Health Improvement and Research grant no. CRF2020-2-4025Sanming Project of Medicine in Shenzhen No. SZSM201911008
6 · The paper itself

Abstract

purposeThis study aims to provide a simple indicator for predicting the prognosis of cancer survivors and offer reference and guidance for management strategies to ultimately improve their long-term prognosis.

methodsBased on data from the 1999-2019 National Health and Nutrition Examination Survey, we included 3436 cancer survivors in this study. Participants were defined as cancer survivors if they had been previously diagnosed with cancer by a doctor or health professional. The neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and systemic inflammatory response index (SIRI) were used as systemic inflammatory markers. Survival status was determined by linking it with National Death Index records. Associations between systemic inflammatory markers and cancer survivor prognoses were evaluated using weighted Cox regression, Kaplan-Meier survival curves, and restricted cubic spline curves.

resultsAll three systemic inflammatory markers were significantly associated with cancer survivor prognoses after adjusting for confounders. NLR and SIRI were positively associated with all-cause mortality (ACM), while LMR was negatively associated with ACM in cancer survivors. The hazard ratios and 95% confidence interval were 1.10 (1.07-1.14), 1.16 (1.10-1.21) and 0.91 (0.87-0.95) respectively. In addition, a significant nonlinear correlation was observed between LMR and the prognosis of cancer survivors (P for nonlinear < 0.05).

conclusionsNLR, SIRI, and LMR were independent predictors of prognosis in cancer survivors. NLR and SIRI were positively associated with ACM, while LMR was negatively associated with ACM. IMPLICATIONS FOR CANCER SURVIVORS: Systemic inflammatory markers may help predict outcomes and inform care strategies for cancer survivors.

Indexed as

Cancer survivorsPrognostic indicatorsSurvival analysisSystemic inflammatory markers

Identifiers

PMID40676441
PMCPMC12271561

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.